Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
TG Therapeutics
TGTX
TG Therapeutics
Pricing Pressures And Competitive Risks Will Impair Market Strength
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
04 May 25
Updated
16 Aug 25
2
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$12.34
127.6% overvalued
intrinsic discount
16 Aug
US$28.08
Loading
1Y
27.2%
7D
5.1%
Author's Valuation
US$12.3
127.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
1
Shared on
08 May 25
Read more
0
votes
Share
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$12.3
127.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-345m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.0b
Earnings US$336.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
26.40%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$336.61m
Earnings '28
x
6.83x
PE Ratio '28
=
US$2.30b
Market Cap '28
US$2.30b
Market Cap '28
/
153.48m
No. shares '28
=
US$14.97
Share Price '28
US$14.97
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$12.30
Fair Value '25
